Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.


Journal

Cytometry. Part A : the journal of the International Society for Analytical Cytology
ISSN: 1552-4930
Titre abrégé: Cytometry A
Pays: United States
ID NLM: 101235694

Informations de publication

Date de publication:
09 2019
Historique:
received: 27 12 2018
revised: 04 06 2019
accepted: 05 06 2019
pubmed: 1 8 2019
medline: 2 10 2020
entrez: 1 8 2019
Statut: ppublish

Résumé

Flow cytometry is broadly used for the identification, characterization, and monitoring of hematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centers. Since 2006, the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centers in France about the standardized instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centers, in France and in Belgium. The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Intercenter reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the median fluorescence intensities (MFIs) of the markers tested. Intracenter reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. © 2019 International Society for Advancement of Cytometry.

Identifiants

pubmed: 31364809
doi: 10.1002/cyto.a.23844
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1008-1018

Informations de copyright

© 2019 International Society for Advancement of Cytometry.

Références

Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111(8):3941-3967.
Preijers FW, Huys E, Favre C, Moshaver B. Establishment of harmonization in immunophenotyping: A comparative study of a standardized one-tube lymphocyte-screening panel. Cytometry B Clin Cytom 2014;86(6):418-425.
Fuertes I. Towards harmonization or standardization in governmental accounting? The international public sector accounting standards board experience. J Comp Policy Anal 2008;10(4):327-345.
Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: aconsensus proposal of the European Leukemia Net Work Package 10. Leukemia 2011;25(4):567-574.
Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S, Almeida J, del Carmen Garcia-Macias M, Bottcher S, Van Dongen JJ, et al. Automated pattern-guided principal component analysis vsexpert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia 2010;24(11):1927-1933.
Feller N, van der Velden VH, Brooimans RA, Boeckx N, Preijers F, Kelder A, de Greef I, Westra G, Te Marvelde JG, Aerts P, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129.
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31(10):2094-2103.
Johansson U, Bloxham D, Couzens S, Jesson J, Morilla R, Erber W, Macey M, British Committee for Standards in Haematology. Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in haematology. Br J Haematol 2014;165(4):455-488.
Novakova M, Glier H, Brdickova N, Vlkova M, Santos AH, Lima M, Roussel M, Flores-Montero J, Szczepanski T, Bottcher S, et al. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. J Immunol Methods 2017; pii: S0022-1759(17)30139-4.
Preijers FW, van der Velden VH, Preijers T, Brooimans RA, Marijt E, Homburg C, van Montfort K, Gratama JW. Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward. Cytometry B Clin Cytom 2016;90(3):267-278.
Solly F, Rigollet L, Baseggio L, Guy J, Borgeot J, Guérin E, Debliquis A, Drenou B, Campos L, Lacombe F, et al. Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. Cytometry A 2013;83(12):1066-1072.
Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling A, Gaipa G, Bartels M, Sobral da Costa E, Kotrová M, Novakova M, Sonneveld E, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2017;129(3):347-357.
Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, et al. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet working group. Leukemia 2012;26(7):1730-1741.
Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B ClinCytom 2007;72(Suppl 1):S14-S22.
Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonca A, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26(9):1986-2010.
van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensionalflow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26(9):1908-1975.
Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VHJ, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, et al. Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 2015;87(2):145-156.
Glier H, Heijnen I, Hauwel M, Dirks J, Quarroz S, Lehmann T, Rovo A, Arn K, Matthes T, Hogan C, et al. Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. J Immunol Methods 2017; pii:S0022-1759(17)30205-3.
Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108(4):378-382.

Auteurs

Françoise Solly (F)

CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France.
CHU Vaudois-Lausanne, Laboratoire d'hématologie, Lausanne, Switzerland.

Fanny Angelot-Delettre (F)

Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France.
Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.

Michel Ticchioni (M)

CHU de Nice, Laboratoire d'Immunologie, Nice, France.

Franck Geneviève (F)

CHU Angers, Laboratoire d'Hématologie Fédération Hospitalo-Universitaire GOAL, Grand Ouest Against Leukemia, Angers, France.

Hubert Rambaud (H)

CHU Angers, Laboratoire d'Hématologie Fédération Hospitalo-Universitaire GOAL, Grand Ouest Against Leukemia, Angers, France.

Lucile Baseggio (L)

Centre Hospitalier Lyon Sud Hospices civils de Lyon, Laboratoire d'hématologie, Lyon, France.

Adriana Plesa (A)

Centre Hospitalier Lyon Sud Hospices civils de Lyon, Laboratoire d'hématologie, Lyon, France.

Agathe Debliquis (A)

Groupe Hospitalier de la région Mulhouse sud Alsace, Laboratoire d'Hématologie, Mulhouse, France.

Francine Garnache-Ottou (F)

Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France.
Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.

Anne Roggy (A)

Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France.

Lydia Campos (L)

CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France.

Carmen Aanei (C)

CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France.

Alessandra Rosenthal-Allieri (A)

CHU de Nice, Laboratoire d'Immunologie, Nice, France.

Marie-Thérèse Georget (MT)

CHRU de Tours, Service d'Hématologie Biologique, Tours, France.

Sébastien Lachot (S)

CHRU de Tours, Service d'Hématologie Biologique, Tours, France.

Marie-Christine Jacob (MC)

CHU de Grenoble, Immunology, Grenoble, France.

Nelly Robillard (N)

CHU de Nantes, Laboratoire d'hématologie, Nantes, France.

Soraya Wuilleme (S)

CHU de Nantes, Laboratoire d'hématologie, Nantes, France.

Elisabeth Andre-Kerneis (E)

Centre Hospitalier Henri Duffaut, Laboratoire d'Hématologie, Avignon, France.

Edouard Cornet (E)

CHU Caen, Laboratoire d'Hématologie; INSERM U1245, Group Biomarkers of lymphoma and solid Tumors Equipe MICAH, Caen, France.

Véronique Salaun (V)

Centre Hospitalier Universitaire de Caen, Laboratoire d'hématologie, Caen, France.

Hind Bennami (H)

Institut Curie, Laboratoire d'hématologie, Saint-Cloud, France.

Anne-Catherine Lhoumeau (AC)

CRCM, Aix Marseille Univ, CNRS, Inserm, Marseille, France.

Christine Arnoulet (C)

Institut Paoli-Calmettes, Département de Biologie du cancer, Institut Paoli-Calmettes, Département de Biologie du cancer, Marseille, France.

Hugues Jacqmin (H)

CHU UCL Namur, Laboratoire d'Hématologie, Namur, Belgium.

Nicolas Neyman (N)

CHU UCL Namur, Laboratoire d'Hématologie, Namur, Belgium.

Véronique Latger-Cannard (V)

Centre Hospitalier Universitaire de Nancy, Plateforme de cytometrie en flux, Nancy, France.

Fredéric Massin (F)

Centre Hospitalier Universitaire de Nancy, Plateforme de cytometrie en flux, Nancy, France.

Elodie Lainey (E)

Hôpital Robert Debré- APHP, Service d'Hématologie Biologique, Hôpital Robert Debré- APHP, UMRS_1131- Institut Universitaire d'Hématologie, Paris, France.

Magali Le Garff-Tavernier (M)

Groupe Hospitalier Pitié-Salpêtrière, UF Phénotypage des Hémopathies, Centre d'Ecologie Cellulaire, Service d'hématologie Biologique, Paris, France.

Myrto Costopoulos (M)

Groupe Hospitalier Pitié-Salpêtrière, UF Phénotypage des Hémopathies, Centre d'Ecologie Cellulaire, Service d'hématologie Biologique, Paris, France.
INSERM U1138, Programmed Cell Death and Physiopathology of Tumor Cells Centre de recherche des cordeliers, Paris, France.

Mickael Roussel (M)

CHU de Rennes, Laboratoire Hématologie, Rennes, France.

Caroline Mayeur-Rousse (C)

CHU Strasbourg, Laboratoire d'hématologie, Strasbourg, France.

Alice Eischen (A)

CHU Strasbourg, Laboratoire d'hématologie, Strasbourg, France.

Victoria Raggeneau (V)

CH Versailles, Service de biologie médicale, Unité d'hématologie et de cytogénétique onco hématologique, Versailles, France.

Coralie Derrieux (C)

Grand Hôpital de l'Est Francilien, Laboratoire d'Hématologie, Meaux, France.

Maxime Maurer (M)

Hôpitaux Civils de Colmar, Laboratoire d'Hématologie, Colmar, France.

Vahid Asnafi (V)

Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.
Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Amélie Trinquand (A)

Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.
Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Chantal Brouzes (C)

Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.
Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Ludovic Lhermitte (L)

Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.
Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH